

Anton Pottegård (brief CV)

Professor, University of Southern Denmark
Head of Research, Hospital Pharmacy, Odense University Hospital

Mobile phone: +45 28913340
E-mail: apottegaard@health.sdu.dk
ORCID: 0000-0001-9314-5679
Homepage: www.antonpottegard.dk
Born 1986



This is an abbreviated resume. Supplementary information is available [HERE](#) and a publication list [HERE](#).

Education

2019 Doctor in Medical Sciences (DMSc) at University of Southern Denmark
Thesis: Pharmacoepidemiological assessment of drug-cancer associations
2012-2014 PhD in Pharmacoepidemiology at University of Southern Denmark
Thesis: Pharmacoepidemiological aspects of vitamin K antagonist treatment (main supervisor: Jesper Hallas)
2009-2011 Master in Clinical Pharmacy at University of Southern Denmark
2006-2009 Bachelor in Pharmacy at Copenhagen University

Occupational experience

2019-Present University of Southern Denmark, professor
2023-Present The Hospital Pharmacy at Odense University Hospital, Researcher
2016-2023 The Hospital Pharmacy at Odense University Hospital, Head of Research
2016-2019 University of Southern Denmark, associate professor
2011-2017 Copenhagen Sønderbro Pharmacy, project pharmacist
2014-2016 University of Southern Denmark, PostDoc
2011-2014 University of Southern Denmark, PhD-student
2012-2013 Capital Region Pharmacy, project manager
2011 Danish Medicines Agency, Institute for Rational Pharmacotherapy, project employee

Academic commissions of trust (selected)

2021-2022 Chair of Scientific Program Committee and Host of the 2022 Annual ICPE Conference for the International Society for Pharmacoepidemiology in Copenhagen, Denmark
2021 Guest editor for special issue on 'translational pharmacology' in Basic and Clinical Pharmacology and Toxicology together with Tore B. Stage
2020-2021 Member of ISPE Real-World-Evidence Task Force
2020-2021 Project lead appointed by Danish Medicines Agency on a large-scale academic-regulator collaboration (DACCOWID) performing pharmacoepidemiological analyses to support Danish and international regulatory decision-making during the covid-19 pandemic
2020-2021 Co-chair of ISPE-ISPOR Special Task Force on harmonization of research protocols
2017-2019 Chair of the Education Committee at International Society for Pharmacoepidemiology
2017-Present Assistant editor for the journal Basic and Clinical Pharmacology and Toxicology (BCPT)
2013-2019 Chair of the Danish Society for Pharmacoepidemiology

Honors and awards (selected)

2022 Honorary Medal from the Danish Society Theoretical and Applied Therapy (Jakobinerklubben)
2022 Elite Research Prize for outstanding young researchers from the Danish Ministry of Higher Education and Science (200,000dkk personal award and 1,000,000dkk research award)
2021 Sapere Aude Research Leader grant from the Danish Independent Research Council (4.3 mill dkk research award)
2020 BCPT Young Researcher Nordic Prize for outstanding contribution to pharmacological research
2015 Lundbeck Foundation Young Researcher Talent Award (100,000dkk personal award)

Grants, research contracts and international collaborations (selected)

I have published together with 600+ researchers from all over the world (examples include US, Australia, Taiwan, Japan, South Korea, Ghana, the Scandinavian countries, UK, Germany, Holland, Spain, and Canada) and am, or have been involved in, several large-scale international collaborations either collaborator or principal investigator (PI). Further, I have successfully obtained funding from several Danish funds such as the Velux Foundation or the Danish Council for Independent Research. Finally, I serve as PI for several large-scale contracts for regulator-mandated phase IV-studies funded by the industry with funds paid to my institution. The examples below are selected to exemplify these categories.

Hypothesis-free screening for adverse events: A new approach in drug safety research (2022-present)

Role: PI

Funding: €573,000 from the Danish Council of Independent Research (2021; Sapere Aude)

Project: We will develop methodology allowing hypothesis-free screening of real-world healthcare data in drug safety research. Specifically, we will complete four work packages tackling (i) design challenges related to the detection of adverse cardio-vascular events, (ii) use of 'active comparators' to reduce confounding, (iii) prioritization of signals, and (iv) automated external replication of potential safety findings. In doing so, it is the ambition to establish hypothesis-generating screening studies as a new approach in pharmacoepidemiology, which can ultimately change pharmacovigilance practices worldwide.

Psychotropic medications and Glioma: an international pharmacoepidemiological study (2020-present)

Role: Co-investigator (PI: Blánaid Hicks, Queens University, Belfast, Ireland)

Funding: £170,098 obtained from Cancer Research UK (2020; Prevention and Population Research Project Grant).

Project: Glioma causes significant morbidity and mortality worldwide and treatment options remain limited. With this project, we aim to set up an international multicenter study from the UK, Denmark, Sweden, Norway, and the USA, to investigate (i) the association between antidepressant use and glioma risk and (ii) the use of psychotropic medications among glioma patients.

Improving the quality of observational studies on drug-cancer associations (2017-2020)

Role: PI

Funding: dkk2,214,720 from the Danish Council of Independent Research (2017; Project 1, Medical Sciences)

Project: In this PhD project (student: Kasper B. Kristensen), we develop new insights in addressing common issues related to confounding in pharmacoepidemiological drug-cancer studies. The project is conducted in collaboration with the Danish Cancer Society, Harvard University, and Kaiser Permanente and aims to increase the overall quality of research in this field and, ultimately, drug safety.

Mapping attitudes towards deprescribing and developing a medication discontinuation model (2017-2021)

Role: PI

Funding: €162,000 (2017) and €215,000 (2019) from the Velux Foundation.

Project: Deprescribing is increasingly recognized as a potential solution to the increasing medication use among older people, particularly those in the last years of life. In this project, we explored patients', relatives' and health care professionals' attitudes towards deprescribing in older people with limited life expectancy in a series of systematic reviews, interview studies, and questionnaire-based studies. Based on our findings, we developed a comprehensive and patient-centered deprescribing intervention which is currently tested in a randomized clinical trial among older people with a life expectancy shorter than two years.

Epidemiological assessment of the risk for pancreatic cancer associated with the use of semaglutide in patients with type 2 diabetes - A cohort study based on Nordic registry data (2019-2026)

Role: PI

Budget: €1,613,000 overall budget of which €993,000 goes to the University of Southern Denmark. Funded by Novo Nordisk A/S.

Project: A potential risk of pancreatic cancer has been hypothesized for incretin mimetic class of antidiabetic drugs, including the Glucagon-like peptide-1 (GLP-1) analogues. In this regulator-mandated post-authorization safety study (PASS), we will set up an international multicenter study from Denmark, Sweden and Norway to evaluate whether exposure to semaglutide (an GLP-1 analogue) influences the risk of pancreatic cancer in patients with type 2 diabetes.

Publications and citations

My publications currently include **330 peer-reviewed articles** (302 original articles and 28 reviews) of which I am the **primary author of 52**, second author of 72 and **last author of 91** (leaving 115 as an ‘in-between’ author). I have furthermore been involved in 7 editorials/commentaries, 1 case report, 13 letters, 2 book-chapters, and 100+ posters. Lastly, I have authored one full textbook in pharmacology.

My research has been published in high-ranking general journal such as BMJ, JAMA, and JAMA Internal Medicine, as well as high-ranking specialist journals such as Lancet Infectious Diseases, Gut, International Journal of Epidemiology, Journal of the American College of Cardiology (JACC), and many others. Overall, **39% of my publications are accepted into top10% most cited journals** (source: Scopus 2015-2020; CiteScore-metric) and 66% of my publications are made available as Open Access. I have been **cited 6297 times** and I have an **H-index of 38** (source: Web of Science; updated January 2023). Similar numbers according to Google Scholar are 9817 and 47. I maintain a considerable international network, and as a result, 43% of my publications are a product of international collaboration, while 38% is with national collaborators and only 19% is authored solely with colleagues from my own institutions (source: Scopus 2015-2020; Collaboration-metric).

Invited talks

I have been invited to give 30+ presentations at national and international scientific conferences and meetings, mainly in relation to my work within pharmacoepidemiology and clinical pharmacy. Selected examples include presenting the results from the Danish covid-19 project (DACCVID) at the International Conference of Pharmacoepidemiology, presenting our findings on hydrochlorothiazide and skin cancer risk at numerous international dermatological and cardiovascular meetings, and as keynote presenting the possibilities of using real-world data in the study of drug effects at the Nordic Conference on Real World data (Helsinki 2016). In addition, I am frequently asked to give guest lectures at various institutions, such as internal sessions at Harvard University, Toulouse University Hospital, the Danish Medicines Council, and at the Danish Cancer Society.

Review

I am active as a reviewer with high-ranking general journals such as the New England Journal of Medicine (NEJM), The Lancet, Journal of the American Medical Association (JAMA), and British Medical Journal (BMJ), high-ranking specialist journals such as Journal of the American College of Cardiology (JACC), Thorax, and JAMA Psychiatry, as well as epidemiological and pharmacological journals such as Epidemiology, American Journal of Epidemiology, Clinical Epidemiology, Pharmacoepidemiology and Drug Safety, Basic and Clinical Pharmacology and Toxicology, and British Journal of Clinical Pharmacology.

Supervision and Teaching

I have been (or am currently) a supervisor for 23 PhD-students, eight of which as the main supervisor (four completed and four ongoing). Further, I have been a supervisor for countless (100+) students during their Bachelor's or Master's thesis projects. I am the Head of Studies for the Pharmacist education at the University of Southern Denmark and I am teaching at a wide range of courses (e.g., pharmacists and medical students and at the PhD school), in addition to being course lead for the Master's course “Evidence-based medicine” for clinical pharmacists. Finally, I am involved in numerous recurring course activities within the International Society for Pharmacoepidemiology and the Danish Society for Pharmacoepidemiology.

Outreach and dissemination

I am convinced of the importance of curating the findings from my research, e.g. via social media where I maintain active profiles on both Twitter (3500+ followers) and LinkedIn (3200+ connections). I use these channels to promote our findings, often in the form of short videos or similar walkthroughs, as well as to engage with other researchers and organizations. Out of the 289 publications tracked by Altmetric, 75% received attention (their DOIs were cited in newspaper, policy documents or social media) with a total of 6000+ mentions. Altmetric also recorded 17 mentions of my publications in clinical guidelines and policy papers (excluding Danish clinical guidelines) including 3 citations by the World Health Organization. In addition, I frequently publish laymen articles describing our research findings, e.g., via ScienceNordic.com, the Danish ForskerZonen or LinkedIn. Finally, I contribute actively to the public debate on use of medicines and on health science in general.